Home > Boards > US Listed > Biotechs > Sorrento Therapeutics, Inc. (SRNE)

CNBC just announced the interview next.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
svknight Member Profile
 
Followed By 1
Posts 22
Boards Moderated 0
Alias Born 11/11/09
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:01:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2021 1:37:13 PM
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 GlobeNewswire Inc. - 9/13/2021 9:00:00 AM
Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients GlobeNewswire Inc. - 9/2/2021 11:34:20 AM
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern GlobeNewswire Inc. - 8/26/2021 3:42:09 PM
Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device GlobeNewswire Inc. - 8/26/2021 12:28:06 PM
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University GlobeNewswire Inc. - 8/24/2021 10:44:48 AM
Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel GlobeNewswire Inc. - 8/23/2021 3:52:24 PM
Will Sorrento’s Promising COVID-19 Vaccine Results Boost Stock? TipRanks - 8/20/2021 11:02:54 AM
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern GlobeNewswire Inc. - 8/19/2021 4:21:34 PM
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives GlobeNewswire Inc. - 8/19/2021 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/11/2021 9:02:25 AM
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics GlobeNewswire Inc. - 8/11/2021 9:00:00 AM
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics GlobeNewswire Inc. - 8/11/2021 8:35:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2021 3:46:51 PM
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program GlobeNewswire Inc. - 8/9/2021 2:39:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2021 5:31:57 PM
Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model GlobeNewswire Inc. - 8/4/2021 12:57:08 PM
Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS... GlobeNewswire Inc. - 8/3/2021 9:00:00 AM
Sorrento Gets Fed Go-Ahead to Test Myeloma Med TipRanks - 8/3/2021 6:39:19 AM
Sorrento gets FDA greenlight for early-stage CD38 DAR-T multiple myeloma study Seeking Alpha - 8/2/2021 9:10:00 AM
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma GlobeNewswire Inc. - 8/2/2021 9:00:00 AM
First patient enrolled in China Oncology's late-stage socazolimab lung cancer trial Seeking Alpha - 7/23/2021 11:55:45 AM
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer GlobeNewswire Inc. - 7/23/2021 11:37:37 AM
Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors GlobeNewswire Inc. - 7/21/2021 2:09:52 PM
svknight   Monday, 05/18/20 10:14:56 AM
Re: None
Post # of 11378 
CNBC just announced the interview next.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences